Ekso Bionics Holdings Inc (EKSO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Ekso Bionics Holdings Inc stock (EKSO) is currently trading at $10.98. Ekso Bionics Holdings Inc PS ratio (Price-to-Sales) is 2.93. Analyst consensus price target for EKSO is $9.50. WallStSmart rates EKSO as Sell.
- EKSO PE ratio analysis and historical PE chart
- EKSO PS ratio (Price-to-Sales) history and trend
- EKSO intrinsic value — DCF, Graham Number, EPV models
- EKSO stock price prediction 2025 2026 2027 2028 2029 2030
- EKSO fair value vs current price
- EKSO insider transactions and insider buying
- Is EKSO undervalued or overvalued?
- Ekso Bionics Holdings Inc financial analysis — revenue, earnings, cash flow
- EKSO Piotroski F-Score and Altman Z-Score
- EKSO analyst price target and Smart Rating
Ekso Bionics Holdings Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Ekso Bionics Holdings Inc (EKSO) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Ekso Bionics Holdings Inc (EKSO) Key Strengths (0)
Ekso Bionics Holdings Inc (EKSO) Areas to Watch (8)
Company is destroying shareholder value
Losing money on operations
Revenue declining -38.30%, a shrinking business
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 4.1x book value
Low institutional interest, mostly retail-driven
Revenue is fairly priced at 2.93x sales
Supporting Valuation Data
Ekso Bionics Holdings Inc (EKSO) Detailed Analysis Report
Overall Assessment
This company scores 18/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 0 register as strengths (avg 0/10) while 8 fall into concern territory (avg 2.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (2.93), Price/Book (4.14) suggest expensive pricing. Growth concerns include Revenue Growth at -38.30%, which may limit upside. Profitability pressure is visible in Return on Equity at -107.60%, Operating Margin at -119.70%, Profit Margin at -91.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -107.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -38.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
EKSO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
EKSO's Price-to-Sales ratio of 2.93x trades 169% above its historical average of 1.09x (94th percentile), historically expensive. The current valuation is 55% below its historical high of 6.47x set in Feb 2014, and 4790% above its historical low of 0.06x in May 2025. Over the past 12 months, the PS ratio has expanded from ~0.1x, reflecting growing market expectations outpacing revenue growth.
Compare EKSO with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Ekso Bionics Holdings Inc (EKSO) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Ekso Bionics Holdings Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 13M with 38% decline year-over-year. The company is currently unprofitable, posting a -91.4% profit margin.
Key Findings
Revenue contracted 38% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -91.4% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Ekso Bionics Holdings Inc.
Bottom Line
Ekso Bionics Holdings Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Ekso Bionics Holdings Inc(EKSO)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the United States and internationally. The company is headquartered in Richmond, California.